Skip to Content

Zingo Approval History

  • FDA approved: Yes (First approved August 16th, 2007)
  • Brand name: Zingo
  • Generic name: lidocaine hydrochloride monohydrate
  • Dosage form: Dermal PowderJect
  • Company: Anesiva, Inc.
  • Treatment for: Local Anesthesia

Zingo (lidocaine hydrochloride monohydrate) is a needle-free, local anesthetic intradermal injection system, which provides rapid, topical, local analgesia to reduce the pain associated with venous access procedures, such as IV insertions or blood draws.

Development History and FDA Approval Process for Zingo

Jan  9, 2009Approval Anesiva Announces FDA Approval of sNDA to Expand Zingo Indication to Include Adults
Aug 17, 2007Approval Anesiva Receives FDA Approval for Zingo, a New, Innovative Productto Reduce Pain Associated with Needle Insertion Procedures inChildren
Apr 10, 2007Endo Comments on Notices Received From Anesiva Regarding Zingo
Feb  7, 2007Anesiva Announces FDA Acceptance for Filing of Zingo New Drug Application to Reduce Pain Associated With Needle Insertion Procedures in Children
Nov 27, 2006Anesiva Announces Filing of New Drug Application for Zingo to Reduce Pain Associated with Needle Insertion Procedures in Children

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.